TG Therapeutics Files 8-K Report
Ticker: TGTX · Form: 8-K · Filed: May 1, 2024 · CIK: 1001316
Sentiment: neutral
Topics: financial-results, 8-k, company-update
Related Tickers: TGTX
TL;DR
TG Therapeutics dropped its 8-K, check the financials.
AI Summary
On May 1, 2024, TG Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, previously known as Manhattan Pharmaceuticals Inc., Atlantic Technology Ventures Inc., and Atlantic Pharmaceuticals Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This filing provides an update on TG Therapeutics' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting financial results and does not appear to contain any immediately alarming information.
Key Players & Entities
- TG Therapeutics, Inc. (company) — Registrant
- Manhattan Pharmaceuticals Inc. (company) — Former Company Name
- Atlantic Technology Ventures Inc. (company) — Former Company Name
- Atlantic Pharmaceuticals Inc. (company) — Former Company Name
- May 1, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report by TG Therapeutics, Inc. pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on its results of operations and financial condition, as well as financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 1, 2024.
What is TG Therapeutics, Inc.'s fiscal year end?
TG Therapeutics, Inc.'s fiscal year ends on December 31.
What is the company's business address?
The company's business address is 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014.
What are some of the former names of TG Therapeutics, Inc.?
Some of the former names of TG Therapeutics, Inc. include Manhattan Pharmaceuticals Inc., Atlantic Technology Ventures Inc., and Atlantic Pharmaceuticals Inc.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-05-01 07:05:25
Filing Documents
- tgtx20240430_8k.htm (8-K) — 25KB
- ex_664535.htm (EX-99.1) — 108KB
- 0001437749-24-014062.txt ( ) — 277KB
- tgtx-20240501.xsd (EX-101.SCH) — 3KB
- tgtx-20240501_def.xml (EX-101.DEF) — 11KB
- tgtx-20240501_lab.xml (EX-101.LAB) — 15KB
- tgtx-20240501_pre.xml (EX-101.PRE) — 11KB
- tgtx20240430_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 1, 2024, TG Therapeutics, Inc. (the "Company") issued a press release announcing results of operations for the three months ended March 31, 2024. A copy of such press release is being furnished as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release issued by TG Therapeutics, Inc., dated May 1, 2024. Exhibit 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TG Therapeutics, Inc. (Registrant) Date: May 1, 2024 By: /s/ Sean A. Power Sean A. Power Chief Financial Officer